A Novel Diagnostic Option for Biochemically Recurrent Prostate Cancer Diagnosis - Part 2
We now have some new weapons in our prostate cancer arsenal. In part 2 of this video presentation, the speaker will be discussing prostate cancer imaging with AxuminTM (fluciclovine F18) PET/CT Scan and their initial commercial experience with the product. Topics include prescribing and important safety information, molecular structure, bio-distribution, guided lymph node dissection, positive diagnostic criteria and a review of case studies using the product.
By the end of the session, the attendee will be able to: Describe the important safety and prescribing information of Axumin™ (fluciclovine F18) Describe the molecular structure and bio-distribution of Axumin™ (fluciclovine F18) Describe the procedure for guided lymph node dissection and the positive diagnostic criteria for prostate cancer. The attendee should now be able to: Describe the important safety and prescribing information of Axumin™ (fluciclovine F18) Describe the molecular structure and bio-distribution of Axumin™ (fluciclovine F18) Describe the procedure for guided lymph node dissection and the positive diagnostic criteria for prostate cancer. Select the link below to launch the video in a separate window. Webinar Video A Novel Diagnostic Option for Biochemically Recurrent Prostate Cancer Diagnosis Part 2
- Biochemically Recurrent Prostate Cancer